Identifying new gene spliceosomes in children with neuroblastoma
Identification of New Gene Spliceosomes in Neuroblastoma and Their Translational Application in Clinical Accurate Diagnosis and Therapy
This study looks at the genes in children with neuroblastoma to see how their cancer is different and to find new ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 1 Day to 14 Years |
| Sex | All |
| Sponsor | Affiliated Hospital of Nantong University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Nantong, Jiangsu) |
| Trial ID | NCT06502210 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze the genetic makeup of children diagnosed with neuroblastoma by utilizing advanced sequencing technologies, including Deep Sequencing and Third Generation Sequencing. Researchers will collect tumor and adjacent normal tissues from 20 children to identify differentially expressed genes and specific transcript variants associated with cancer differentiation. The study will also explore potential therapeutic targets and assess the impact of genetic variations on treatment outcomes. By comparing tumor tissues with normal tissues, the research seeks to enhance understanding of neuroblastoma's biological diversity.
Who should consider this trial
Good fit: Ideal candidates are children aged 0 to 14 diagnosed with neuroblastoma who are physically fit for surgery and chemotherapy.
Not a fit: Patients with distant metastasis, severe organ dysfunction, or autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for children with neuroblastoma.
How similar studies have performed: While similar studies have explored genetic factors in neuroblastoma, this specific approach using advanced sequencing technologies is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children with neuroblastoma range in age from 0 to 14, regardless of gender; * Preoperative imaging examinations indicate patient with neuroblastoma; * Before postoperative chemotherapy, the patient's physical strength is good. At the same time, the results of white blood cells, neutrophils, hemoglobin, platelets, and other test indicators are all within normal range, which is in line with the treatment conditions of the relevant chemotherapy and immunotherapy; * Preoperative pathological examination of the patient reveals neuroblastoma; * Patients have no other history of malignant tumors; * Patients voluntarily participate and sign informed consent and can comply with the study visit plan and other protocol requirements. Exclusion Criteria: * Patients who are found to have distant metastasis or ascites on preoperative examination are excluded; * Patients with severe liver and kidney dysfunction, as well as those with autoimmune diseases are excluded; * Patients with severe cardiovascular disease who can not tolerate general anesthesia are excluded; * Patients who have other malignancies or blood disorders are excluded.
Where this trial is running
Nantong, Jiangsu
- Affiliated Hospital of Nantong University — Nantong, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Wenliang Ge, archiater
- Email: gewl@ntu.edu.cn
- Phone: 0086-13962854122
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.